Literature DB >> 9657472

Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries.

K Kugiyama1, H Doi, T Motoyama, H Soejima, K Misumi, H Kawano, O Nakagawa, M Yoshimura, H Ogawa, T Matsumura, S Sugiyama, T Nakano, K Nakajima, H Yasue.   

Abstract

BACKGROUND: It remains undetermined whether triglyceride-rich lipoproteins are an independent risk factor for atherosclerosis. METHODS AND
RESULTS: The correlation of responses of coronary arterial diameter (quantitative coronary angiography) and coronary blood flow (intracoronary flow wire technique) to intracoronary infusion of acetylcholine (10 and 50 microg/min) with coronary risk factors including remnant lipoprotein levels was statistically analyzed in 106 consecutive subjects with normal coronary angiograms. Remnant lipoproteins were isolated from fasting blood with an immunoaffinity mixed gel containing anti-apolipoprotein (apo) A-1 and anti-apoB-100 monoclonal antibodies. In multivariate stepwise regression analysis, remnant lipoprotein levels had the most significant correlation with abnormal epicardial coronary vasomotor responses to acetylcholine infusion, reflected by impaired dilation or constriction of the epicardial coronary arteries, and the levels also had an inverse and independent correlation with the coronary blood flow increase in response to acetylcholine. In a subgroup of 53 consecutive subjects, constrictor responses of epicardial coronary diameters to intracoronary infusion of NG-monomethyl-L-arginine (50 micromol/min for 4 minutes) at baseline, reflecting the presence of coronary nitric oxide bioactivity, had an inverse and independent correlation with remnant lipoprotein levels by use of multivariate analysis.
CONCLUSIONS: Remnant lipoprotein levels were independently associated with abnormal endothelium-dependent vasomotor function in large and resistance coronary arteries in humans, indicating that remnant lipoproteins may impair endothelial vasomotor function in human coronary arteries. The decrease in coronary nitric oxide bioactivity may be responsible in part for the inhibitory effects of remnant lipoproteins.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657472     DOI: 10.1161/01.cir.97.25.2519

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  22 in total

Review 1.  Postprandial lipemia and cardiovascular disease.

Authors:  Dianne Hyson; John C Rutledge; Lars Berglund
Journal:  Curr Atheroscler Rep       Date:  2003-11       Impact factor: 5.113

Review 2.  Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

Authors:  Richard J Woodman; Gerard T Chew; Gerald F Watts
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis?

Authors:  Francine K Welty
Journal:  Curr Cardiol Rep       Date:  2013-09       Impact factor: 2.931

Review 4.  Postprandial lipoprotein metabolism: VLDL vs chylomicrons.

Authors:  Katsuyuki Nakajima; Takamitsu Nakano; Yoshiharu Tokita; Takeaki Nagamine; Akihiro Inazu; Junji Kobayashi; Hiroshi Mabuchi; Kimber L Stanhope; Peter J Havel; Mitsuyo Okazaki; Masumi Ai; Akira Tanaka
Journal:  Clin Chim Acta       Date:  2011-04-19       Impact factor: 3.786

5.  Lipid-lowering and anti-inflammatory effect of ezetimibe in hyperlipidemic patients with coronary artery disease.

Authors:  Tetsuya Tobaru; Atsushi Seki; Ryuta Asano; Tetsuya Sumiyoshi; Nobuhisa Hagiwara
Journal:  Heart Vessels       Date:  2012-03-17       Impact factor: 2.037

6.  Identification of ACOX2 as a shared genetic risk factor for preeclampsia and cardiovascular disease.

Authors:  Asa Johansson; Joanne E Curran; Matthew P Johnson; Katy A Freed; Mona H Fenstad; Line Bjørge; Irina P Eide; Melanie A Carless; David L Rainwater; Harald H H Goring; Rigmor Austgulen; Eric K Moses; John Blangero
Journal:  Eur J Hum Genet       Date:  2011-02-23       Impact factor: 4.246

Review 7.  ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.

Authors:  Natalia A Rocha; Cara East; Jun Zhang; Peter A McCullough
Journal:  Curr Atheroscler Rep       Date:  2017-11-09       Impact factor: 5.113

8.  Effect of the Probiotic Saccharomyces boulardii on Cholesterol and Lipoprotein Particles in Hypercholesterolemic Adults: A Single-Arm, Open-Label Pilot Study.

Authors:  Jennifer Joan Ryan; Douglas Allen Hanes; Morgan Beth Schafer; Jeremy Mikolai; Heather Zwickey
Journal:  J Altern Complement Med       Date:  2015-04-20       Impact factor: 2.579

Review 9.  Mechanism of differential effects of antihypertensive agents on serum lipids.

Authors:  R D Brook
Journal:  Curr Hypertens Rep       Date:  2000-08       Impact factor: 5.369

10.  High remnant lipoprotein levels in patients with variant angina.

Authors:  Kunihisa Miwa; Toshinori Makita; Katsuhisa Ishii; Nobuaki Okuda; Ataru Taniguchi
Journal:  Clin Cardiol       Date:  2004-06       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.